Johnson & Johnson
General ticker "JNJ" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $392.5B (TTM average)
Johnson & Johnson follows the US Stock Market performance with the rate: 40.3%.
Estimated limits based on current volatility of 0.7%: low 203.12$, high 205.82$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-08-26, amount 1.30$ (Y2.57%)
- Total employees count: 139800 as of 2024
- Top business risk factors: Geopolitical risks, Litigation risks, Product liability, Intellectual property risks, Supply chain disruptions
- Current price 17.4% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-29 to 2026-12-29
- 2024-12-29 to 2025-12-29 estimated range: [120.43$, 172.49$]
- 2025-12-29 to 2026-12-29 estimated range: [126.14$, 179.24$]
Financial Metrics affecting the JNJ estimates:
- Negative: with PPE of 14.5 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 24.94 > 18.64
- Positive: 6.82 < Operating cash flow per share per price, % of 6.95
- Positive: Inventory ratio change, % of 0.68 <= 0.84
- Negative: 0.01 < Interest expense per share per price, % of 0.22
- Positive: -14.38 < Investing cash flow per share per price, % of -5.33
- Positive: 18.93 < Shareholder equity ratio, % of 39.69 <= 41.86
- Positive: Return on assets ratio (scaled to [-100,100]) of 7.24 > 6.04
- Positive: Industry earnings per price (median), % of 5.01 > 4.43
- Positive: Industry inventory ratio change (median), % of -2.14 <= -0.15
Short-term JNJ quotes
Long-term JNJ plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-29 |
|---|---|---|
| Operating Revenue | $85,159.00MM | $88,821.00MM |
| Operating Expenses | $61,750.00MM | $66,672.00MM |
| Operating Income | $23,409.00MM | $22,149.00MM |
| Non-Operating Income | $-8,347.00MM | $-5,462.00MM |
| Interest Expense | $772.00MM | $755.00MM |
| R&D Expense | $15,085.00MM | $17,232.00MM |
| Income(Loss) | $15,062.00MM | $16,687.00MM |
| Taxes | $1,736.00MM | $2,621.00MM |
| Other Income(Loss) | $21,827.00MM | $0.00MM |
| Profit(Loss)* | $56,980.00MM | $14,066.00MM |
| Stockholders Equity | $68,774.00MM | $71,490.00MM |
| Inventory | $11,181.00MM | $12,444.00MM |
| Assets | $167,558.00MM | $180,104.00MM |
| Operating Cash Flow | $22,791.00MM | $24,266.00MM |
| Capital expenditure | $4,543.00MM | $4,424.00MM |
| Investing Cash Flow | $878.00MM | $-18,599.00MM |
| Financing Cash Flow | $-15,825.00MM | $-3,132.00MM |
| Earnings Per Share** | $22.49 | $5.84 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.